Plasma biomarkers of brain atrophy in Alzheimer's disease

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Thambisetty, Madhav ^a   Simmons, Andrew ^b   Hye, Abdul ^b   Campbell, James ^c   Westman, Eric ^b   Zhang, Yi ^d   Wahlund, Lars Olof ^d   Kinsey, Anna ^b   Causevic, Mirsada ^b   Killick, Richard ^b   Kloszewska, Iwona ^e   Mecocci, Patrizia ^f   Soininen, Hilkka ^g   Tsolaki, Magda ^h   Vellas, Bruno ⁱ   Spenger, Christian ^d   Lovestone, Simon ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Proteome Sciences plc   (United Kingdom)

^d KAROLINSKA INSTITUTE   (Sweden)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f UNIVERSITY OF PERUGIA   (Italy)

^g UNIVERSITY OF EASTERN FINLAND   (Finland)

^h ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

ⁱ Hopitaux de Toulouse   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 MICROGLOBULIN; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT FACTOR I; FIBRINOGEN; GAMMA FIBRINOGEN; UNCLASSIFIED DRUG; PLASMA PROTEIN;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD CLOTTING; BRAIN ATROPHY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME IMMUNOASSAY; FEMALE; HIPPOCAMPUS; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; SEX; ATROPHY; BLOOD; BRAIN; METABOLISM; ORGAN SIZE; PATHOLOGY; REGRESSION ANALYSIS; REPRODUCIBILITY;

AGED; ALZHEIMER DISEASE; ATROPHY; BIOLOGICAL MARKERS; BLOOD PROTEINS; BRAIN; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; MALE; ORGAN SIZE; REPRODUCIBILITY OF RESULTS;

EID: 83755185924     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028527     Document Type: Article

References (28)

1. Cummings JL, Doody R, Clark C, (2007) Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 69: 1622-1634.
2. Lovestone S, Francis P, Strandgaard K, (2007) Biomarkers for disease modification trials-the innovative medicines initiative and AddNeuroMed. J Nutr Health Aging 11: 359-361.
3. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, et al. (2005) Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement 1: 55-66.
4. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, et al. (2006) Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129: 3042-3050.
5. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group (1998) Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". Neurobiol Aging 19: 109-116.
6. Schneider JA, Arvanitakis Z, Bang W, Bennett DA, (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69: 2197-2204.
7. Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, et al. (2010) Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 67: 739-748.
8. Simmons A, Westman E, Muehlboeck S, Mecocci P, Vellas B, et al. (2011) The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. Int J Geriatr Psychiatry 26: 75-82.
9. Alzheimer's Association (2004) Research consent for cognitively impaired adults: recommendations for institutional review boards and investigators. Alzheimer Dis Assoc Disord 18: 171-175.
10. Karas G, Sluimer J, Goekoop R, van der Flier W, Rombouts SA, et al. (2008) Amnestic mild cognitive impairment: structural MR imaging findings predictive of conversion to Alzheimer disease. AJNR Am J Neuroradiol 29: 944-949.
11. Smith SM, Rao A, De Stefano N, Jenkinson M, Schott JM, et al. (2007) Longitudinal and cross-sectional analysis of atrophy in Alzheimer's disease: cross-validation of BSI, SIENA and SIENAX. Neuroimage 36: 1200-1206.
12. Zijdenbos AP, Forghani R, Evans AC, (2002) Automatic "pipeline" analysis of 3-D MRI data for clinical trials: application to multiple sclerosis. IEEE Trans Med Imaging 21: 1280-1291.
13. Jack CR Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, et al. (2008) The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 27: 685-691.
14. Stove S, Welte T, Wagner TO, Kola A, Klos A, et al. (1996) Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome. Clin Diagn Lab Immunol 3: 175-183.
15. Mattila KM, Frey H, (1995) Two-dimensional analysis of qualitative and quantitative changes in blood cell proteins in Alzheimer's disease: search for extraneuronal markers. Appl Theor Electrophor 4: 189-196.
16. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, et al. (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13: 1359-1362.
17. Murphy DG, DeCarli CD, Daly E, Gillette JA, McIntosh AR, et al. (1993) Volumetric magnetic resonance imaging in men with dementia of the Alzheimer type: correlations with disease severity. Biol Psychiatry 34: 612-621.
18. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, et al. (2005) Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64: 1563-1572.
19. Wahlund LO, Blennow K, (2003) Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 339: 99-102.
20. Bonifati DM, Kishore U, (2007) Role of complement in neurodegeneration and neuroinflammation. Mol Immunol 44: 999-1010.
21. Shen Y, Meri S, (2003) Yin and Yang: complement activation and regulation in Alzheimer's disease. Prog Neurobiol 70: 463-472.
22. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH, (2007) Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol 61: 120-129.
23. Simonsen AH, McGuire J, Hansson O, Zetterberg H, Podust VN, et al. (2007) Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol 64: 366-370.
24. Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, et al. (2011) Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One 6: e18850.
25. Thambisetty M, An Y, Kinsey A, Koka D, Saleem M, et al. (2012) Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage 59: 212-217.
26. van Oijen M, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM, (2005) Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke 36: 2637-2641.
27. Thambisetty M, Hye A, Foy C, Daly E, Glover A, et al. (2008) Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J Neurol 255: 1712-1720.
28. Mills S, Cain J, Purandare N, Jackson A, (2007) Biomarkers of cerebrovascular disease in dementia. Br J Radiol 80 Spec No 2: S128-145.